Peritonitis - Pipeline Review, H1 2018

Peritonitis - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Peritonitis - Pipeline Review, H1 2018, provides an overview of the Peritonitis (Gastrointestinal) pipeline landscape.

Peritonitis is inflammation of the peritoneum. There are two types of peritonitis. Spontaneous bacterial peritonitis (SBP) is the result of an infection of the fluid in peritoneal cavity. Secondary peritonitis is usually due to an infection that has spread from digestive tract. Symptoms include abdominal bloating, nausea and vomiting, diarrhea, fatigue, fever and chills. Treatment includes antibiotics.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Peritonitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Peritonitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritonitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peritonitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Peritonitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peritonitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Peritonitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peritonitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peritonitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peritonitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peritonitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peritonitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Peritonitis - Overview 6
Peritonitis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 12
Peritonitis - Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Peritonitis - Companies Involved in Therapeutics Development 21
Adenium Biotech ApS 21
GlaxoSmithKline Plc 21
Oncodesign SA 21
SynAct Pharma AB 22
Peritonitis - Drug Profiles 23
AA-139 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
AcPepA - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
AP-1189 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
molgramostim - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
R-10001 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecules to Inhibit Nitric Oxide Synthase for Rheumatism, Arthritis and Peritonitis - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
SRT-3025 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Peritonitis - Dormant Projects 34
Peritonitis - Product Development Milestones 35
Featured News & Press Releases 35
Jun 19, 2016: Reponex Pharmaceuticals: The Danish Medicines Agency has approved the clinical trial protocol for the peritonitis project 35
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List Of Tables

List of Tables
Number of Products under Development for Peritonitis, H1 2018 7
Number of Products under Development by Companies, H1 2018 9
Number of Products under Development by Universities/Institutes, H1 2018 10
Products under Development by Companies, H1 2018 11
Products under Development by Universities/Institutes, H1 2018 12
Number of Products by Stage and Target, H1 2018 14
Number of Products by Stage and Mechanism of Action, H1 2018 16
Number of Products by Stage and Route of Administration, H1 2018 18
Number of Products by Stage and Molecule Type, H1 2018 20
Peritonitis - Pipeline by Adenium Biotech ApS, H1 2018 21
Peritonitis - Pipeline by GlaxoSmithKline Plc, H1 2018 21
Peritonitis - Pipeline by Oncodesign SA, H1 2018 22
Peritonitis - Pipeline by SynAct Pharma AB, H1 2018 22
Peritonitis - Dormant Projects, H1 2018 34

List Of Figures

List of Figures
Number of Products under Development for Peritonitis, H1 2018 7
Number of Products under Development by Companies, H1 2018 8
Number of Products by Targets, H1 2018 13
Number of Products by Stage and Targets, H1 2018 13
Number of Products by Mechanism of Actions, H1 2018 15
Number of Products by Stage and Mechanism of Actions, H1 2018 15
Number of Products by Routes of Administration, H1 2018 17
Number of Products by Stage and Routes of Administration, H1 2018 17
Number of Products by Molecule Types, H1 2018 19
Number of Products by Stage and Molecule Types, H1 2018 19

Spontaneous Bacterial Peritonitis Global Clinical Trials Review, H2, 2018

Spontaneous Bacterial Peritonitis Global Clinical Trials Review, H2, 2018The clinical trial report, Spontaneous Bacterial Peritonitis Global Clinical Trials Review, H2, 2018 provides an overview of Spontaneous Bacterial Peritonitis clinical trials

USD 2500 View Report

Peritonitis Global Clinical Trials Review, H1, 2018

Peritonitis Global Clinical Trials Review, H1, 2018GlobalDatas clinical trial report, Peritonitis Global Clinical Trials Review, H1, 2018 provides an overview of Peritonitis clinical trials scenario. This report provides top line

USD 2500 View Report

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2018

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1)

USD 3500 View Report

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H2 2018

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H2 2018Phosphatidylinositol 4,5

USD 3500 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available